RxDoctor Payments DataLook up a doctor →

Sabahat Bokhari, MD

Cardiovascular Disease · Allentown, PANPI 1831288158

Payments from drug & device makers

$791,460in general payments, 2019–2025

Across 494 payments — averaging $1602.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$262K
  • AstraZeneca$125K
  • Pfizer$107K
  • Cleerly, Inc.$106K
  • Bridgebio Pharma, Inc.$65K
  • Eidos Therapeutics, Inc.$35K
  • plus $91K from 8 others

What the payments were for

  • Consulting fees$65,33411%
  • Speaking & faculty fees$465,03180%
  • Travel & lodging$35,9666%
  • Food & beverage$11,8162%
  • Education$970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$791,460 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$92,907
Medicare patients
610
Services billed
1,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis348$8,224,382
CamzyosMavacamten41$320,004
VyndaqelTafamidis Meglumine12$210,177
EntrestoSacubitril/Valsartan13$17,280
FarxigaDapagliflozin Propanediol16$15,209
Torsemide16$434
Atorvastatin Calcium36$430
Rosuvastatin Calcium11$299
Verapamil ErVerapamil Hcl11$296
Metoprolol Succinate39$294
Spironolactone15$132
Lisinopril20$125
Clonidine Hcl13$122
Furosemide27$97
Amlodipine Besylate21$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel$106,550$8,434,559360 claims
E.r. Squibb & Sons, L.L.C.Camzyos$15,843$320,00441 claims
AstraZenecaFarxiga$125,083$15,20916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →